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Abstract
Background: Effective prevention of excessive alcohol use has the potential to reduce the public burden of disease
considerably. We investigated the cost-effectiveness of Screening and Brief Intervention (SBI) for excessive alcohol use in
primary care in the Netherlands, which is targeted at early detection and treatment of ‘at-risk’ drinkers.
Methodology and Results: We compared a SBI scenario (opportunistic screening and brief intervention for ‘at-risk’ drinkers)
in general practices with the current practice scenario (no SBI) in the Netherlands. We used the RIVM Chronic Disease Model
(CDM) to extrapolate from decreased alcohol consumption to effects on health care costs and Quality Adjusted Life Years
(QALYs) gained. Probabilistic sensitivity analysis was employed to study the effect of uncertainty in the model parameters. In
total, 56,000 QALYs were gained at an additional cost of J298,000,000 due to providing alcohol SBI in the target population,
resulting in a cost-effectiveness ratio of J5,400 per QALY gained.
Conclusion: Prevention of excessive alcohol use by implementing SBI for excessive alcohol use in primary care settings
appears to be cost-effective.
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Introduction
Excessive alcohol use is a cause of morbidity and even mortality,
as it increases risks of coronary heart disease, stroke, and several
types of cancers, withassociated losses of life-years and quality of life
[1,2,3]. In addition, substantial disability from medical and
psychiatric consequences, injuries and ‘‘secondhand’’ effects (e.g.
motor vehicle crashes) are attributed to excessive use of alcohol [4].
In the Netherlands, about 1% of total mortality, 4.5% of the
public burden of disease and 0.6% of total health care costs (in
2003) can be attributed to chronic diseases caused by excessive
alcohol consumption [5]. Currently, about 14% of Dutch men
aged 12 or above drink more than three alcoholic consumptions
per day and about 10% of the Dutch women aged 12 or above
drink more than two alcoholic consumptions per day [6].
As a result, effective prevention of excessive alcohol use has the
potential to reduce the burden of disease in the Netherlands
considerably. Brief intervention for excessive alcohol use in
primary care settings is an effective intervention [7,8,9,10,11]. In
a randomized study, Fleming et al. [7,8] found significant
reductions in 7-day alcohol use in patients who received brief
physician advice 12 months after the intervention. Senft et al. [9]
also found significant reductions in numbers of weekly drinking
days 12 months after receiving the brief intervention. Bertholet et
al. [10] indicated that brief intervention in primary care resulted in
a reduction in weekly ethanol intake of 38 grams per person. Also
randomized trials conducted in other settings have demonstrated a
reduction in the intake of alcohol by three to nine drinks per week,
as compared to the control group [11]. In order to recognize and
treat patients with alcohol problems, an opportunistic screening
program should be included in the general practices. Fiellin et al.
[12] evaluated the accuracy of screening methods for alcohol
problems in primary care. The Alcohol Use Disorders Identifica-
tion Test (AUDIT) was most effective in identifying subjects with
at-risk, hazardous, or harmful drinking. Sensitivity of this
questionnaire ranged from 51% to 97%, while specificity ranged
from 78% to 96%. While screening would be opportunistic and
not targeted at any group specifically, brief intervention is targeted
at groups with a high risk to be(come) an excessive drinker in
primary care. High risk groups are defined as women who drink 2
or more standard alcohol drinks (i.e. .20 grams ethanol) per day;
and men who drink 4 or more standard alcohol drinks (i.e.
.40 grams ethanol) per day; without meeting the DSM-IV
criteria for alcohol dependency [13].
In the present study, we performed a cost-effectiveness analysis
(CEA) of SBI in primary care patients. The outcome of this CEA is
expressed as a ratio of incremental costs relative to incremental
effects of the intervention: the incremental cost-effectiveness ratio
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Years) [14]. We performed our assessment using a dynamic model
for the entire Dutch population (the RIVM Chronic Disease
Model (CDM)), taking a healthcare perspective focusing on health
benefits and health care costs. The health care costs included are
the costs of opportunistic screening, costs of brief intervention, the
costs of alcohol related diseases and costs of diseases unrelated to
alcohol in life years gained. There are previous studies which
investigated the cost-effectiveness of interventions similar to SBI
[15,16,17,18,19] e.g. Fleming et al. 2000 [19] calculated from the
societal perspective that the benefit-cost ratio of the brief
intervention was 5.6:1, or $56,263 in total benefit for every
$10,000 invested. Only one of the previous studies [15]
investigated the cost-effectiveness of SBI in costs per QALY
gained. However, this study did not take into account the medical
costs of diseases unrelated to alcohol in life years gained and did
not account for the fact that quality of life decreases at older ages.
Results
The total Dutch population aged 20–65 years accounts for about
10 million people. On average 6,176,000 of them are screened
during the opportunistic screening programme. As table 1 shows,
1,386,000 excessive and dangerous drinkers exist in the Dutch
populationaged20–65.Onaverage853,000 ofthemarefound with
the screening instrument, and 577,000 of them receive the brief
intervention. This results in 39,000 people becoming moderate
drinkers or abstain from alcohol, which is about 3% of the amount
of excessive drinkers in the Dutch population aged 20–65.
In the SBI scenario the reduction in alcohol consumption results
in a decrease in the incidence of alcohol related diseases, and in a
decrease in health care costs of these diseases. As a consequence,
this causes a gain in life years and QALYs compared to current
practice scenario (no provision of SBI). Figure 1 displays a costs
(differences in intervention+lifetime health care costs) and effects
(QALYs gained) plane for SBI scenario compared to current
practice scenario, for different values of the model input
parameters.
This figure displays the results of a PSA. Each point represents
incremental costs and effects of one run of the CDM, taking as
input a random sample drawn from the distributions of the model
parameters. The spread of the cloud of points in the figure shows
the uncertainty in the estimation of the joint distribution of costs
and effects. As can be seen from this figure, health care costs
increase as the amount of QALYs gained increases. If the numbers
of person receiving SBI increases, both costs of SBI will increase,
and the amount of QALYs gained.
Incremental life years gained, QALYs gained, health care costs
incurred and the resulting ICER for the SBI scenario are shown in
Table 2.
Table 1. Impact of the SBI. Estimates and their 95% confidence interval (between brackets).
N
Total Dutch population aged 20–65 years 10,029,000*
Number of excessive and dangerous drinkers in total Dutch population aged 20–65 years 1,386,000*
Number of persons screened in the opportunistic screening programme in the GP practice 6,176,000 (5,740,000–6,545,000)
Number of excessive and dangerous drinkers found during the screening programme 853,000 (793,000–904,000)
Number of excessive and dangerous drinkers receiving the brief intervention 577,000 (389,000–734,000)
Number of drinkers who became moderate drinkers or abstained from alcohol 39,000 (2,000–92,000)
*Derived from the annual General Public Health and Lifestyle Survey (Dutch initials: POLS) conducted by Statistics Netherlands.
doi:10.1371/journal.pone.0005696.t001
Figure 1. Incremental costs and effects of SBI compared to current practice scenario for the target population.
doi:10.1371/journal.pone.0005696.g001
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scenario compared to the current practice scenario. Mean
incremental costs per life year gained are J3,600 for the SBI
scenario compared to the current practice scenario. When only
cost of SBI itself would be included in the denominator of the
ICER, mean costs per QALY and per life year gained would be
respectively J1,100 and J700,- for the SBI scenario compared to
current practice scenario. Costs per QALY are higher than costs
per life year gained in this scenario. This is because the number of
QALYs gained falls short of the numbers of life years gained, since
not all life years gained are lived in perfect health.
Regarding the effect of the alcohol SBI in the long run, Figure 2
displays costs per QALY gained for different fractions of effect
maintained in long run.
The figure shows that costs per QALY decrease as the fraction
of effect maintained in the long run increases. This is due to an
increase in the amount of QALYs gained from a maintained
reduction in alcohol consumption in the long run. It should be
noted that if no effect is maintained at all in the long run, the costs
per QALY gained would be infinitely high.
Figure 3 represents the Cost-Effectiveness Acceptability Curve
for the SBI scenario, which displays the probability that the
alcohol SBI is cost effective for different values of the threshold, i.e.
for different monetary values placed on a QALY [14,20].
When, for instance, a QALY is valued at J5,000, implementing
alcohol SBI is cost effective with a probability of 0.4. Alcohol SBI
has a probability of almost one when the society is willing to pay
J10,000 per QALY, which is well below the threshold usually
placed on a QALY in the Netherlands (J20,000 per QALY
gained). This means that alcohol SBI can be considered cost
effective.
Discussion
Excessive alcohol use increases risks of many disorders, with
associated losses of life-years and quality of life. Successful
prevention of excessive alcohol consumption will therefore result
in increased life expectancy and decreased health care costs. From
a health care perspective, implementing SBI in primary care
setting in The Netherlands would lead to health gains at a low
cost. The cost-effectiveness of SBI was estimated at J5,400 per
QALY gained and, thus, can be considered cost-effective.
Effectiveness
In several randomized studies, alcohol brief intervention has
been proven to be effective in reducing excessive alcohol use
[7,8,9,10,11]. However, Beich et al. [11] indicate that the numbers
of patients needed to screen (NNS) in general practices is quite
high to achieve benefits, because only two to three patients per
thousand screened benefit from the laborious activities entailed in
screening. But, we demonstrated that opportunistic screening is
relatively cheap since all patients are already present in the waiting
room of the GP.
Cost-effectiveness
Previous research studies investigating the cost-effectiveness of
interventions similar to alcohol SBI also considered this type of
intervention to be cost-effective [15,16,17,18,19]. However, these
studies did not always express the outcome measure in terms of
QALYs. Only Solberg et al. [15], when ranking the health impact
and cost effectiveness of alcohol primary care intervention to
reduce alcohol misuse did this in terms of QALYs gained.
However, Solberg et al. [15] did not take into account the medical
costs of diseases unrelated to alcohol in life years gained.
Table 2. Estimates of total incremental costs and effects due
to SBI intervention and their 95% confidence interval
(between brackets).
SBI scenario vs. current
practice scenario
Life years gained
a (*1,000) 82 (35/140)
QALYs gained
a (*1,000) 56 (24/94)
Costs SBI (* J1,000,000)
b 61 (48/70)
Total costs differences (* J1,000,000)
b 298 (146/514)
J per life year gained
c* 700
J per QALY gained
c* 1,100
J per life year gained
c 3,600
J per QALY gained
c 5,400
aDiscounted with 1.5%.
bDiscounted with 4%.
cQALYs and life years gained discounted with 1.5% and costs discounted with
4%.
*Only SBI costs included.
doi:10.1371/journal.pone.0005696.t002
Figure 2. Costs per QALY gained for different fractions of effect maintained in long run.
doi:10.1371/journal.pone.0005696.g002
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life decreases at older ages [21]. Wutzke et al. [16] expressed the
outcome measure only as costs per life year saved by preventing
alcohol-related deaths, and did not include the initial costs of
screening. Babor et al. [17] took as their outcome measure the
intervention costs per reduction in alcohol consumption per
patient, again not the amount of QALYs gained.
Assumptions
In this study, we made some assumptions that need to be
confirmed by further research. The long term effects of alcohol
SBI are debatable. Babor et al. [22] indicated that long term
effects on population health had not yet been demonstrated.
Wutzke et al. [23] conclude that there is no effect of alcohol SBI
without any regular check-ups after 10 years. However, Nilssen
[24] conclude that the impact of brief interventions for individuals
who are at increased risk but not (yet) meeting the DSM-IV
criteria for alcohol dependency appears to be long lasting, up till 9
years after the provision of alcohol SBI. In our study, we took into
account the uncertainty regarding the long term persistence of the
effect by incorporating a ‘‘bandwidth’’ for the part of the short
term decrease in alcohol consumption that is conserved in the long
run, including the possibility that no effect remains. It is obvious to
note that if there would be no more effect of alcohol SBI in the
long term, then the cost-effectiveness ratios of this intervention
would increase substantially.
Limitations
One limitation of our analysis is that external effects of
implementing the alcohol SBI were ignored because a health
care perspective was taken. We have solely focused on health care
costs, ignoring broader costs and consequences (like damage done
due to violence and accidents induced by drinking) of a reduction
of excessive alcohol consumption which fall outside the scope of
the health care budget. However, these broader costs seem to be
related mostly to drinking patterns [25]. The model we employed
only models the relation between average alcohol consumption on
quality of life, mortality and health care costs which corresponds
well to the outcome measures reported in the brief intervention
trials. In case brief intervention would have any effect on alcohol
patterns, brief intervention is expected to be more cost-effective,
and maybe even cost-saving.
Insummary,preventionofexcessive alcoholusebyimplementing
the alcohol SBI in a GP setting appears to be cost-effective, with
mean incremental costs of J5,400 per QALY gained. The findings
of this alcohol SBI economic evaluation implicate that such an
intervention is a wise use of health care resources to reduce the
public burden of diseases related to excessive alcohol use.
Methods
Intervention
SBI for excessive alcohol use in medical settings entails two
elements: 1) opportunistic screening in a primary care setting (i.e. a
General Practice) to identify excessive drinkers; 2) brief interven-
tion: a low-intensity, short-duration counselling intervention of 10
to 15 minutes, with feedback about drinking, advice and goal
setting, and a follow-up contact (one or more discussions lasting 10
to 15 minutes with a primary care physician).
Scenarios
To estimate the effects of SBI, the two following scenarios were
compared:
– Current Practice scenario: in this scenario nobody in the
Dutch population is screened for alcohol consumption and
alcohol consumption patterns remain at their current level;
– SBI scenario: all persons between age 20 and age 65 who visit
the GP within one year are screened and those who are identified
as excessive drinkers receive the brief intervention. Due to brief
intervention alcohol consumption patterns are altered.
The SBI scenario entails the following steps [26]:
1) All patients visiting general practice are approached by a GP-
assistant when they are in the waiting room during a regular
visit, i.e. not specifically for alcohol related complaints. They
Figure 3. Cost-effectiveness acceptability curve for alcohol SBI scenario.
doi:10.1371/journal.pone.0005696.g003
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validated alcohol screening instrument developed by the
World Health Organization [27];
2) Completed questionnaires are scored by the GP. Those
identified as excessive drinkers (an AUDIT-score of 8+) and
not meeting the DSM-IV criteria for alcohol dependency are
administered the Brief Intervention;
3) The GP provides follow-up sessions at 6 and 12 months.
The RIVM Chronic Disease Model
We estimated incremental health effects and costs by comparing
the two scenarios. To extrapolate from decreased alcohol
consumption as a result of the intervention to effects on health
care costs, life years gained and QALYS gained, we used the
RIVM Chronic Disease Model (CDM) [28,29,30]. The CDM is a
tool that relates (changing) prevalences of risk factors in the general
population, such as smoking, overweight and alcohol consump-
tion, to the occurrence of chronic diseases. It has been used for
projections into the future, as well as to estimate health adjusted
life expectancy and to perform cost effectiveness analysis
[21,31,32,33,34]. The model describes the life course of cohorts
in terms of changes between risk factor classes and changes
between disease states over time. It allows for co-morbidity and
includes epidemiological data on the most important chronic
diseases and their risk factors. Risk factors and diseases are linked
through relative risks for disease incidence. Alcohol consumption is
included as a risk factor that is linked to the following diseases:
coronary heart disease, stroke, oesophagus cancer, breast cancer,
oral cavity cancer and larynx cancer. Alcohol consumption is
divided into the following classes: abstinence (no alcohol
consumption), moderate alcohol consumption (less than 2
standard drink units per day, for women, or 4 units for men),
excessive alcohol consumption (between 2 and 4 standard drink
units per day, respectively 4 and 6 for men) and dangerous alcohol
consumption (more than 4, respectively 6 standard drink units per
day) [35]. The distribution over these classes of alcohol
consumption patterns of the current Dutch population was
estimated using data from the annual General Public Health
and Lifestyle Survey (Dutch initials: POLS) conducted by Statistics
Netherlands [36].
The relative risks for the diseases related to alcohol consumption
and all cause mortality employed in the CDM were all derived
from the meta-analysis by Holman et al. [35]. This was the only
study that included relative risk estimates for the alcohol categories
employed in the CDM for both diseases and mortality, and that
provided estimates of all-cause mortality. Such a category of all-
cause mortality was not used in other studies on relative risks of
alcohol consumption. In the simulation model we used these
estimates of relative risks on total mortality to estimate the effects
of alcohol on mortality through causes of death that are not
explicitly in our model.
In essence, our model compared the current distribution of
alcohol consumption according to the classes distinguished in the
model to the distribution that would result from the intervention.
In order to estimate this new ‘‘post-intervention’’ distribution, we
again used the POLS data mentioned above, but this time
subtracting from the raw data the average decrease in alcohol
consumption due to SBI for every individual in the data set having
the characteristics of the target population, and then re-estimating
the alcohol consumption distribution.
To calculate the decrease in alcohol consumption due to SBI we
multiplied the sensitivity of the screening instrument by the
decrease in alcohol consumption times the long term maintenance
fraction. The long term maintenance fraction is the fraction of the
decrease in alcohol consumption that can be sustained in the long
run. It is assumed that only this fraction results in health gains.
To compute health effects in terms of QALYs, the CDM
couples disability weights from the Dutch Burden of Disease Study
to disease prevalence rates [28]. For diseases causally related to
alcohol consumption, we used the CDM to estimate diseases
prevalence rates as a function of time. To capture the impact on
quality of life of diseases not related to alcohol consumption during
life years gained we used age and gender specific prevalence rates
as reported in the Dutch Burden of Disease Study [37]. Cost of
illness (COI) data from the Netherlands for the year 2003 [38]
served to estimate health care expenditure conditional on disease
status and age [31,32]. Annual disease costs per patient were
multiplied by the projected future prevalence numbers for each
alcohol related chronic disease in the model. Costs of all other
diseases, incurred during life years gained, were calculated as the
product of the numbers of ‘‘survivors’’ and the category of
‘remaining costs’. These latter equal the difference between total
health care costs and the costs of the alcohol related diseases
incorporated in the model. They include, for instance, the costs of
mental and behavioural disorders.
Discounting
To calculate cost-effectiveness ratios, yearly differences in model
outcomes between intervention and current practice scenario were
discounted and added over the time horizon to find net present
values for incremental life years gained, QALYs gained, and
health care costs. Future costs and effects were discounted at the
annual percentages of 4% for costs and 1.5% for effects which are
recommended in the Dutch guidelines [39]. The time horizon
chosen was 100 years since by then the cohorts that experienced
the intervention will have become extinct (that is, the cohort was
‘‘followed to extinction’’). We used consumer price indices to
adjust all cost to a 2008 price level.
Derivation of the input parameters for the RIVM CDM
To quantify the costs and effects of the SBI, we needed to make
some assumptions and determine several parameters. Here we
describe how we determined the parameters which we used as
input for the RIVM CDM.
The effectiveness of the Screening and Brief Intervention
First, to estimate the numbers of patients willing to undergo
screening (screening uptake) we calculated a pooled estimate from
all studies described in Solberg et al. [15,40,41,42]. We fitted a
logistic random effects regression model with only a constant to
obtain the estimate and the uncertainty surrounding it. Mean
screening uptake was 86%. Second, for the sensitivity and
specificity of the screening instrument, employing the same
methodology we calculated a pooled estimate from all studies
described in Fiellin et al. [12]. They analyzed the AUDIT
questionnaire as the screening instrument with a cut-off score of
8+, which indicates that a person drinks excessively. Mean
estimate for the sensitivity of the screening instrument was 69%;
and for specificity 94%. Third, as an estimate of the decrease in
alcohol consumption as a result of the brief intervention, we took
the values provided by Bertholet et al. [10] in their systematic
review, namely on average a reduction in weekly ethanol intake of
38 gram per person. With regard to the persistence of the effects of
SBI in the long run, three studies were found showing contrasting
results. Babor et al. [22] indicated that brief intervention can
reduce alcohol use for at least 12 months in non-dependent heavy
drinkers, but long term effects on population health had not yet
Excessive Alcohol Use
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remaining effect after a period of 10 years when there are no
regular check-ups. However, Nilssen [24] concluded that the
impact of a brief intervention appears to be long lasting, up till 9
years after the provision of the intervention.
In our study, we assumed that health effects only accrue if
behavioural changes are maintained lifelong. The fraction of the
initial decrease in alcohol consumption that is maintained in the
long run was drawn from a uniform distribution with minimum 0
and maximum 1.
Costs of the SBI intervention
The costs of opportunistic screening and subsequent interven-
tion were calculated by using a so-called bottom-up method as
advocated in the Dutch Pharmacoeconomic guidelines [43]. All
elements of the screening and intervention were identified and
thereby the resources needed. These units and unit prices are
displayed in Table 3.
Altogether, the screening process costs about J14,- per person.
Providing brief intervention costs about J22,- per person, and
follow-ups costs are J44,- per person.
Target population
In this modelling study, the target population consisted of all
people between age 20 and 65 who visit the GP in a particular
year, which according to Statistics Netherlands (CBS), is
approximately 7.2 million [6].
Table 3. Costs of the SBI intervention, per person.
Type of costs Unit Unit price Costs
Approaching patients by GP-assistant 1 min 0.66 J0.66
Checking AUDIT score 8+, by GP 1 min 2.19 J2.19
Further screening by GP 5 min 2.19 J10.95
Brief intervention by GP 10 min 2.19 J21.9
Follow-up sessions by GP 20 min 2.19 J43.8
doi:10.1371/journal.pone.0005696.t003
Table 4. Summary of assumptions and input data.
Current practice scenario SBI scenario
Assumptions
Discount rate 4% costs and 1.5% effects 4% costs and 1.5% effects
Time horizon 80 years (lifetime) 80 years (lifetime)
Target population Risky drinkers aged between 20 and
65 who visit the GP yearly (50%)
Risky drinkers aged between 20 and 65 who visit the GP yearly (50%)
Distributions used in PSA
Relative risks Lognormal distributions derived from
meta analyses Holman [35]
Lognormal distributions derived from meta analyses Holman [35]
Fraction of the target population that
agrees to be screened
Logit distribution (1/(1+e
2x) with x normally distributed
a:
Mean: 1.802
SD: 0.237
Sensitivity of the screening instrument Logit distribution (1/(1+e
2x) with x normally distributed
b:
Mean: 0.800
SD: 0.490
Specificity of the screening instrument Logit distribution (1/(1+e
2x) with x normally distributed
b:
Mean: 2.763
SD: 0.168
Fraction for second interview Logit distribution (1/(1+e
2x) with x normally distributed
a:
Mean: 1.149
SD: 0.216
Decrease in alcohol consumption Normal distribution
c
Mean: 1.149
SD: 0.216
Fraction of decrease in alcohol
consumption maintained
Uniform distribution
Minimum: 0
Maximum: 1
aPooled estimate from all studies selected and described in Bertholet et al. [10]. A logistic random effects regression analyses with only a constant was carried to obtain
the effect estimate and the uncertainty surrounding it.
bPooled estimate from all studies selected and described in the systematic review by Fiellin et al. [12]. A logistic random effects regression analyses with only a constant
was carried to obtain the effect estimate and the uncertainty surrounding it.
cBertholet et al. [10].
doi:10.1371/journal.pone.0005696.t004
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We used the technique of Probabilistic Sensitivity Analysis (PSA)
to account for uncertainty in the model input parameters. PSA lets
uncertainty in the input parameters be reflected in the model
output (the ICER). We identified and addressed the following
sources of uncertainty in our base-case ICER estimate: the
uncertainty around the relative risk values [35], the values of
screening uptake [15], the sensitivity and specificity of the
screening instrument [12], the follow-up rate of the brief
intervention [10], decrease in alcohol consumption [10], and,
the fraction of decrease in alcohol consumption maintained in the
long run [22,23,24]. Table 4 summarizes the assumptions and the
distributions for the input parameters used in the different
scenarios. In order to perform the analysis the model was run
1000 times. For each run of the model, at random a number is
drawn for each of the ‘‘uncertainty’’ parameters from the
distribution specified for that parameter (see table 4). This leads
to a different output of the model for each run. The variability in
outcome is then a reflection of the uncertainty due to the input
parameters.
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